ArticleNeuroepidemiology2026
Registry-Based Dementia Incidence in Argentina: A Nationwide, Decade-Long Analysis by Age, Sex, and Etiology.
Article in Neuroepidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNational data on dementia incidence are scarce in low- and middle-income countries, limiting public health surveillance and planning. In Argentina, no nationwide estimates of dementia incidence exist despite rapid population aging. Administrative disability registries do not capture clinical disease onset; rather, they record certification events and therefore provide a registry-based proxy for population-level dementia surveillance in settings without prospective incidence cohorts.
methodsWe conducted a population-based registry study using data from Argentina's National Registry of Persons with Disabilities between 2016 and 2022, excluding pandemic-disrupted years (2020-2021). Incident registry entries with dementia recorded as the primary cause of disability were identified using ICD-10 codes for Alzheimer's disease and related disorders (ADRDs), vascular dementia, and other etiologies. Crude and age-standardized incidence (ASI) rates of dementia certification per 100,000 inhabitants were estimated by sex, age group, dementia subtype, and early-onset (<65 years) versus late-onset (≥65 years) dementia. Prespecified sensitivity analyses quantified capture fraction against regional cohorts and adjusted temporal trends for an exogenous proxy of registry maturation.
resultsIn 2022, the registry-based crude dementia incidence was 47.7 per 100,000 inhabitants (95% CI: 46.6-48.7). Crude incidence was higher in women than men, whereas ASI was comparable between sexes (48.1 vs. 45.5 per 100,000). Incidence increased steeply with age, from 0.9 per 100,000 at ages 40-45 years to nearly 480 per 100,000 among individuals aged ≥95 years. ADRDs predominated from approximately 55-60 years onward, while other etiologies were relatively more frequent at younger ages. Late-onset dementia incidence (≥65 years) was substantially higher than early-onset dementia (<65 years) (130.9 vs. 6.3 per 100,000). Provincial age-standardized rates varied from 4.7 to 137.7 per 100,000, and were strongly associated with care access metrics. Between 2016 and 2022, ASI increased significantly (p < 0.001); however, capture fractions were 6-12% relative to regional cohorts, and there was a 45% attenuation of the temporal coefficient after adjustment for registry maturation.
conclusionsThis study provides the first nationwide characterization of registry-based dementia certification incidence in Argentina. Distinct age-, sex-, and etiology-specific patterns highlight different epidemiological scenarios for early- and late-onset dementia. Because these estimates reflect administrative certification rather than clinical disease onset and are subject to differential ascertainment, they should be interpreted as a lower bound of true incidence; nonetheless, they constitute a feasible and informative surveillance approach for countries lacking national clinical registries and can support health system planning and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.